2023 World Conference on Lung Cancer (Posters)-EP12.02. Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs

EP12.02. Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to assess the treatment patterns and economic impact of brain metastases (BM) in patients with anaplastic lymphoma kinase positive (ALK) non-small cell lung cancer (NSCLC) who were receiving next-generation ALK tyrosine kinase inhibitors (TKIs) in the United States (US). The study included adult patients newly diagnosed with ALK NSCLC and BM and treated with next-generation ALK TKIs. Data from three US claims databases were combined and analyzed.<br /><br />The study found that approximately 41.7% of patients had received an ALK TKI prior to their first diagnosis of BM. Among these patients, the majority remained on the same first-line ALK TKI and did not receive additional therapy. Patients who had not yet started ALK TKI treatment at the time of BM diagnosis initiated new treatments within 30 days, with alectinib being the most common choice.<br /><br />The study also assessed the economic burden associated with BM. The median total monthly medical costs post-BM diagnosis were found to be around $20,000. Outpatient visits were the most significant cost driver for both all-cause and BM-related costs.<br /><br />The analysis of a secondary cohort of patients showed an increase in total mean medical costs post-BM diagnosis compared to pre-diagnosis.<br /><br />Overall, the study highlighted the need for effective strategies to delay or prevent the occurrence of BM in patients with ALK NSCLC. It also emphasized the high economic burden associated with BM, underscoring the importance of managing this aspect of the disease. The study had some limitations, including the use of claims databases which may have limitations in data accuracy and the exclusion of indirect costs in the analysis.

Asset Subtitle

Hannah Le

Meta Tag

Speaker Hannah Le

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

brain metastases

anaplastic lymphoma kinase positive

ALK

non-small cell lung cancer

NSCLC

next-generation ALK tyrosine kinase inhibitors

United States

treatment patterns

economic impact

claims databases